Orgenesis shares soar 19% premarket as FDA gives orphan status to insulin tech [MarketWatch]
Orgenesis Inc. (ORGS)
NASDAQ:AMEX Investor Relations:
orgenesis.com
Company Research
Source: MarketWatch
Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech Orgenesis Inc. shares ORGS, -1.83% soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy, caused by chronic pancreatitis. Orgenesis has an exclusive license for the technology from Israel's Tel Hashomer Medical Research Infrastructure and Services Ltd., that is based on the work of Professor Sarah Ferber, the company's chief scientific officer and a researcher at THM. Patients who have total pancreatectomy always suffer from diabetes, which results in lifelong insulin-dependence with the loss of endogenous insulin secretion and that of the counter-regulatory hormone, glucagon. Shares have fallen 8% in 2019, while the S&P 500 SPX, -0.16% has gained 15%.
Show less
Read more
Impact Snapshot
Event Time:
ORGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGS alerts
High impacting Orgenesis Inc. news events
Weekly update
A roundup of the hottest topics
ORGS
News
- Orgenesis Provides Third Quarter 2024 Business UpdateGlobeNewswire
- Orgenesis Commences Trading on OTCQX® Best MarketGlobeNewswire
- Orgenesis Announces Reverse Stock SplitGlobeNewswire
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic LeukemiaGlobeNewswire
ORGS
Sec Filings
- 11/13/24 - Form 10-Q
- 11/12/24 - Form 3
- 11/12/24 - Form 3
- ORGS's page on the SEC website